RaQualia Pharma Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Hirobumi Takeuchi

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	3.3yrs
Eigentum des Geschäftsführers	0.05%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.3yrs

Jüngste Management Updates

Recent updates

Companies Like RaQualia Pharma (TYO:4579) Can Afford To Invest In Growth

Apr 02

The RaQualia Pharma (TYO:4579) Share Price Has Soared 410%, Delighting Many Shareholders

Feb 08

Companies Like RaQualia Pharma (TYO:4579) Can Afford To Invest In Growth

Dec 17

Geschäftsführer

Hirobumi Takeuchi (53 yo)

3.3yrs

Amtszeit

Mr. Hirobumi Takeuchi is President & Chairman of the Board of RaQualia Pharma Inc. from March 2021. He joined the RaQualia Pharma Inc. in March 2021. He served as the Chief Financial Officer at Skylight Bi...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Hirobumi Takeuchi	President & Chairman of the Board	3.4yrs	keine Daten	0.052% ¥ 7.2m
Masaki Sudo	Executive Officer & Director	2.3yrs	keine Daten	0.078% ¥ 10.8m
Katsuhiro Uto	VP & Director	2.3yrs	keine Daten	0.039% ¥ 5.4m
Yuichi Kakinuma	Independent Outside Director	3.3yrs	keine Daten	11.02% ¥ 1.5b
Michihiro Tsuchiya	Independent Outside Director	4.3yrs	keine Daten	keine Daten
Megumi Uzu	Independent Outside Director	3.4yrs	keine Daten	keine Daten
Kosuke Ishii	Independent Outside Director	3.3yrs	keine Daten	keine Daten

3.3yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrener Vorstand: 4579Die Vorstandsmitglieder gelten als erfahren (3.2 Jahre durchschnittliche Amtszeit).

RaQualia Pharma Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

RaQualia Pharma Inc., Annual General Meeting, Mar 26, 2024

No independent directors

No independent directors

RaQualia Pharma Inc., Annual General Meeting, Mar 25, 2022

Recent updates

First quarter 2024 earnings released: JP¥3.61 loss per share (vs JP¥6.86 loss in 1Q 2023)

RaQualia Pharma Inc. (TSE:4579) completed the acquisition of FIMECS, Inc. from Yusuke Tominari, Kamakanae, Nissay Capital No. 11 Investment Limited Partnership managed by Nissay Capital Co., Ltd., ANRI No. 4 Fund managed by ANRI and others.

RaQualia Pharma Inc. (TSE:4579) completed the acquisition of FIMECS, Inc. from Yusuke Tominari, Kamakanae, Nissay Capital No. 11 Investment Limited Partnership managed by Nissay Capital Co., Ltd., ANRI No. 4 Fund managed by ANRI and others.

Full year 2023 earnings: EPS and revenues miss analyst expectations

RaQualia Pharma Inc., Annual General Meeting, Mar 26, 2024

RaQualia Pharma Inc. to Report Q3, 2024 Results on Nov 14, 2024

New minor risk - Market cap size

RaQualia Pharma Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: JP¥6.57 loss per share (vs JP¥0.095 loss in 3Q 2022)

New minor risk - Market cap size

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: JP¥8.00 (vs JP¥28.09 in 2Q 2022)

First quarter 2023 earnings released: JP¥6.86 loss per share (vs JP¥5.73 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

RaQualia Pharma Inc. announced that it has received ¥805.6125 million in funding from CVI Investments, Inc.

RaQualia Pharma Inc. announced that it expects to receive ¥805.6125 million in funding from CVI Investments, Inc.

RaQualia Pharma Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target decreased to JP¥1,200

Third quarter 2022 earnings released: JP¥0.11 loss per share (vs JP¥6.35 loss in 3Q 2021)

No independent directors

Third quarter 2022 earnings released: JP¥0.095 loss per share (vs JP¥6.35 loss in 3Q 2021)

Raqualia Pharma Inc. Provides Consolidated Earnings Guidance for Year Ending December 31, 2022

Second quarter 2022 earnings released: EPS: JP¥28.09 (vs JP¥5.44 in 2Q 2021)

RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to JP¥1,900

No independent directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

RaQualia Pharma Inc., Annual General Meeting, Mar 25, 2022

Third quarter 2021 earnings released: JP¥6.35 loss per share (vs JP¥11.41 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥5.44 (vs JP¥6.25 loss in 2Q 2020)

First quarter 2021 earnings released: EPS JP¥8.97 (vs JP¥15.66 loss in 1Q 2020)

RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021

Full year 2020 earnings released: JP¥28.93 loss per share (vs JP¥0.24 profit in FY 2019)

Companies Like RaQualia Pharma (TYO:4579) Can Afford To Invest In Growth

Revenue and earnings miss expectations

Full year 2020 earnings released: JP¥28.97 loss per share (vs JP¥0.24 profit in FY 2019)

The RaQualia Pharma (TYO:4579) Share Price Has Soared 410%, Delighting Many Shareholders

New 90-day high: JP¥1,110

New 90-day high: JP¥1,105

RaQualia Pharma Inc. to Report Q2, 2021 Results on Aug 12, 2021

Companies Like RaQualia Pharma (TYO:4579) Can Afford To Invest In Growth

New 90-day high: JP¥1,083

Third quarter 2020 earnings released: JP¥11.41 loss per share

New 90-day low - JP¥912

First half earnings released

New 90-day low - JP¥1,012

Geschäftsführer

Amtszeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter